IVX-121
/ AstraZeneca
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 05, 2024
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
(clinicaltrials.gov)
- P1 | N=140 | Completed | Sponsor: Icosavax, Inc. | Active, not recruiting ➔ Completed | Trial primary completion date: Jan 2023 ➔ Jan 2024
Trial completion • Trial primary completion date • Respiratory Diseases • Respiratory Syncytial Virus Infections
June 18, 2023
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
(clinicaltrials.gov)
- P1 | N=120 | Active, not recruiting | Sponsor: Icosavax, Inc. | Recruiting ➔ Active, not recruiting
Enrollment closed • Respiratory Diseases • Respiratory Syncytial Virus Infections
December 23, 2022
Safety and Immunogenicity of IVX-A12 in Healthy Older Adults
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Icosavax, Inc.
New P1 trial • Respiratory Diseases • Respiratory Syncytial Virus Infections
1 to 3
Of
3
Go to page
1